查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611851

蛋白酪氨酸激酶抑制剂市场：按类型、应用和最终用户划分 - 2025-2030 年全球预测

Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

蛋白酪氨酸激酶抑制剂市场2023年估值为590.7亿美元，预计到2024年将达到634.6亿美元，复合年增长率为7.17%，预计到2030年将达到959.5亿美元。

蛋白酪氨酸激酶抑制剂 (TKI) 是一组抑制蛋白酪氨酸激酶的标靶癌症治疗方法，酪胺酸激酶是一种对讯号传导和细胞分裂控制等细胞功能很重要的酵素。 TKI 在治疗各种恶性，包括白血病、肺癌和乳癌，而传统治疗方法往往不足以满足这些癌症的需求。对 TKI 的需求在于它们能够针对特定讯号通路，提供可降低全身毒性并提高患者特异性效率的治疗选择。它的应用范围超出了肿瘤学，包括类类风湿性关节炎和慢性发炎等疾病。最终使用范围主要是医院、专门的癌症治疗中心和专注于个人化医疗的研究机构。

主要市场统计
基准年[2023] 590.7亿美元
预计年份 [2024] 634.6亿美元
预测年份 [2030] 959.5亿美元
复合年增长率（%） 7.17%

市场成长受到全球癌症发生率上升、基因组科学进步以及精准医疗需求增加等因素的显着影响。最近的趋势包括开发具有更高特异性的下一代 TKI，并扩大其在基因治疗和罕见疾病领域的应用。为了利用这些机会，公司应该投资研发合作并鼓励适应性临床试验以加速药物核准。然而，新兴市场面临开发成本高、抗药性突变、重大监管障碍以及安全性和有效性问题等挑战。

创新的治疗领域包括研究将 TKI 和免疫联合治疗结合起来以提高治疗效果，以及利用人工智慧来识别新标靶并优化药物设计，鑑于其独特的性质，这是一个有前途的途径。市场竞争激烈但分散，大型製药企业和快速成长的生物技术公司占据市场主导地位，导致不断创新，但小型企业要成功也需要战略联盟。总之，为了永续成长，该产业应专注于克服抗药性机制、扩大治疗适应症以及提高全球治疗药物的价格和可用性。

市场动态：快速发展的蛋白酪氨酸激酶抑制剂市场的关键市场洞察

蛋白酪氨酸激酶抑制剂市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症流行和标靶治疗的增加
    • 改善天然蛋白酪氨酸激酶抑制剂在医药配方中的使用
  • 市场限制因素
    • 与抗药性发展和药物交互作用相关的限制
  • 市场机会
    • 持续研究活动以提高蛋白酪氨酸激酶抑制剂的质量
    • 政府对蛋白酪氨酸激酶抑制剂的有利核准
  • 市场挑战
    • 对蛋白酪氨酸激酶抑制剂肝毒性的担忧

波特五力：开拓蛋白酪氨酸激酶抑制剂市场的策略工具

波特的五力框架是了解蛋白酪氨酸激酶抑制剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解蛋白酪氨酸激酶抑制剂市场的外部影响

外部宏观环境因素在塑造蛋白酪氨酸激酶抑制剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解蛋白酪氨酸激酶抑制剂市场的竞争格局

对蛋白酪氨酸激酶抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵蛋白酪氨酸激酶抑制剂市场供应商绩效评估

FPNV 定位矩阵是评估蛋白酪氨酸激酶抑制剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了蛋白酪氨酸激酶抑制剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对蛋白酪氨酸激酶抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症流行和标靶治疗的增加
      • 改善天然蛋白酪氨酸激酶抑制剂在药物製剂中的使用
    • 抑制因素
      • 与抗药性发展和配方相互作用相关的限制
    • 机会
      • 持续进行研究活动以提高蛋白酪氨酸激酶抑制剂的质量
      • 政府对蛋白酪氨酸激酶抑制剂的有利核准
    • 任务
      • 对蛋白酪氨酸激酶抑制剂肝毒性的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章蛋白酪氨酸激酶抑制剂市场：依类型

  • BCR-ABL
  • 表皮生长因子受体
  • 血管内皮生长因子受体

第七章蛋白酪氨酸激酶抑制剂市场：依应用分类

  • 乳癌
  • 慢性骨髓性白血病
  • 肺癌
  • 肾臟细胞癌

第八章蛋白酪氨酸激酶抑制剂市场：按最终用户

  • 居家护理
  • 医院
  • 专科诊所

第九章美洲蛋白酪氨酸激酶抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区蛋白酪氨酸激酶抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲蛋白酪氨酸激酶抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline PLC
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals , Inc.
  • Steris Healthcare Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-B168537796FC

The Tyrosine Kinase Inhibitors Market was valued at USD 59.07 billion in 2023, expected to reach USD 63.46 billion in 2024, and is projected to grow at a CAGR of 7.17%, to USD 95.95 billion by 2030.

Tyrosine Kinase Inhibitors (TKIs) are a class of targeted cancer therapies that impede tyrosine kinases-enzymes crucial for cellular functions such as signal transduction and regulation of cell division. The scope of TKIs spans their pivotal role in treating various malignancies, including leukemia, lung cancer, and breast cancer, where traditional therapies often fall short. The necessity of TKIs lies in their ability to target specific signaling pathways, offering a treatment alternative that can reduce systemic toxicity and increase patient-specific efficiency. Their applications extend beyond oncology, including conditions like rheumatoid arthritis and chronic inflammation. The end-use scope is predominantly within hospitals, specialized cancer treatment centers, and research institutions focusing on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 59.07 billion
Estimated Year [2024] USD 63.46 billion
Forecast Year [2030] USD 95.95 billion
CAGR (%) 7.17%

Market growth is influenced heavily by factors such as rising global cancer incidence, advancements in genomics, and increased demand for precision medicine. Recent opportunities include the development of next-generation TKIs with improved specificity and the expansion of their application in gene therapy and rare diseases. To leverage these opportunities, companies should invest in R&D collaborations and encourage adaptive clinical trials to fast-track drug approvals. However, the market faces challenges like high development costs, resistance mutations, and significant regulatory hurdles tied to safety and efficacy concerns.

Innovative areas include exploring combination therapies that pair TKIs with immunotherapies to enhance treatment efficacy, and leveraging artificial intelligence to identify new targets and optimize drug design-a promising avenue given the complex nature of kinase pathways. The market is competitive yet fragmented, dominated by both established pharma giants and burgeoning biotech firms, leading to constant innovation but also necessitating strategic partnerships for smaller players to succeed. In conclusion, for sustained growth, the industry should focus on overcoming resistance mechanisms, expanding therapeutic indications, and addressing the affordability and accessibility of these treatments globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tyrosine Kinase Inhibitors Market

The Tyrosine Kinase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancer and increasing adoption of targeted therapy
    • Improved use of natural tyrosine kinase inhibitors in medical formulations
  • Market Restraints
    • Limitations associated with resistance development and formulation interactions
  • Market Opportunities
    • Ongoing research activities to improve the quality of tyrosine kinase inhibitors
    • Favorable government approvals for Tyrosine Kinase Inhibitors
  • Market Challenges
    • Concerns associated with hepatotoxicity of tyrosine kinase inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Tyrosine Kinase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tyrosine Kinase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tyrosine Kinase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tyrosine Kinase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tyrosine Kinase Inhibitors Market

A detailed market share analysis in the Tyrosine Kinase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tyrosine Kinase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tyrosine Kinase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tyrosine Kinase Inhibitors Market

A strategic analysis of the Tyrosine Kinase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tyrosine Kinase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Cipla Limited, Eisai Co. Ltd., Eli Lilly and Company , F. Hoffmann-La Roche, GlaxoSmithKline PLC, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Johnson & Johnson Services, Inc., Lupin Limited, Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals , Inc., Steris Healthcare Pvt. Ltd., and Takeda Pharmaceutical Company Limited .

Market Segmentation & Coverage

This research report categorizes the Tyrosine Kinase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across BCR-ABL, Epidermal Growth Factor Receptor, and Vascular Endothelial Growth Factor Receptor.
  • Based on Application, market is studied across Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer, and Renal Cell Cancer.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer and increasing adoption of targeted therapy
      • 5.1.1.2. Improved use of natural tyrosine kinase inhibitors in medical formulations
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations associated with resistance development and formulation interactions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to improve the quality of tyrosine kinase inhibitors
      • 5.1.3.2. Favorable government approvals for Tyrosine Kinase Inhibitors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with hepatotoxicity of tyrosine kinase inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tyrosine Kinase Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. BCR-ABL
  • 6.3. Epidermal Growth Factor Receptor
  • 6.4. Vascular Endothelial Growth Factor Receptor

7. Tyrosine Kinase Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Chronic Myeloid Leukemia
  • 7.4. Lung Cancer
  • 7.5. Renal Cell Cancer

8. Tyrosine Kinase Inhibitors Market, by End-Users

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Tyrosine Kinase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tyrosine Kinase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tyrosine Kinase Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Boehringer Ingelheim International
  • 4. Bristol-Myers Squibb Company
  • 5. Cipla Limited
  • 6. Eisai Co. Ltd.
  • 7. Eli Lilly and Company
  • 8. F. Hoffmann-La Roche
  • 9. GlaxoSmithKline PLC
  • 10. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Lupin Limited
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Spectrum Pharmaceuticals , Inc.
  • 16. Steris Healthcare Pvt. Ltd.
  • 17. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. TYROSINE KINASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. TYROSINE KINASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TYROSINE KINASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023